Clinicians Medication overview

Wegovy HD: the original approval overview

Originally posted Mar 2026 · By Joe Zucchi, PA-C, MPAS

Download JPG ↓Original LinkedIn post ↗

1280 × 698 px · PDF includes the original image and a link to this page.

Joe’s commentary

About this visual

A March 2026 visual covering the STEP UP trial and higher-dose semaglutide.

FDA Approves Wegovy HD (7.2 mg Semaglutide) for Chronic Weight Management

On March 19, 2026, the FDA granted approval for Wegovy HD (7.2 mg once-weekly semaglutide injection). This represents the highest dose of injectable semaglutide approved to date for adults with obesity.

The approval is supported by data from the 72-week Phase 3b STEP UP clinical trial, which demonstrated:
- Average Weight Loss: Participants on the 7.2 mg dose achieved an average weight reduction of 20.7%.
- High Response Rate: A significant 31% of participants lost 25% or more of their total body weight.

Wegovy HD is indicated for adults who have established tolerance on the 2.4 mg maintenance dose for at least four weeks, following an established titration pathway, and require further weight loss.

While the overall safety profile is consistent with earlier semaglutide studies, dysesthesia (altered skin sensation) was a notable side effect, reported by 22% of participants on the 7.2 mg dose.

This approval provides a new escalation option within the medical management of obesity. The US launch is anticipated in April 2026.

Sources & further reading

Original LinkedIn post and discussion ↗

Additional references appear in the infographic and the original LinkedIn discussion.

Related visuals

Wegovy HD: the original approval overview

Pinch to zoom on touch devices. Open full image ↗